A Fitchburg company that aims to develop drugs to treat Alzheimer’s disease today announced it has attracted funding that it will use to establish labs, hire scientists and develop drug candidates.
Mithridion Inc. said it has received the first portion of an anticipated $1.6 million in angel funding, with the remainder expected over the next few months.
….Mithridion’s technology was developed at the UW-Madison School of Pharmacy by Jeffrey A. Johnson, an associate professor, and Thor D. Stein, a researcher.